$2.02
0.00% yesterday
NYSE, Nov 25, 10:10 pm CET
ISIN
US1420381089
Symbol
CRBU
Sector
Industry

Caribou Biosciences Stock price

$2.02
+0.25 14.12% 1M
-0.95 31.99% 6M
-3.71 64.75% YTD
-3.73 64.87% 1Y
-15.66 88.57% 3Y
-14.30 87.62% 5Y
-14.30 87.62% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
US1420381089
Symbol
CRBU
Sector
Industry

Key metrics

Market capitalization $182.92m
Enterprise Value $-18.60m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.14
EV/Sales (TTM) EV/Sales -1.62
P/S ratio (TTM) P/S ratio 15.93
P/B ratio (TTM) P/B ratio 0.65
Revenue growth (TTM) Revenue growth -66.85%
Revenue (TTM) Revenue $11.48m
EBIT (operating result TTM) EBIT $-165.18m
Free Cash Flow (TTM) Free Cash Flow $-130.75m
Cash position $228.18m
EPS (TTM) EPS $-1.65
P/E forward negative
P/S forward 17.83
EV/Sales forward negative
Short interest 11.50%
Show more

Is Caribou Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Caribou Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Caribou Biosciences forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Caribou Biosciences forecast:

Buy
78%
Hold
22%

Financial data from Caribou Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
11 11
67% 67%
100%
- Direct Costs 4.72 4.72
10% 10%
41%
6.76 6.76
77% 77%
59%
- Selling and Administrative Expenses 36 36
35% 35%
316%
- Research and Development Expense 131 131
23% 23%
1,141%
-160 -160
54% 54%
-1,398%
- Depreciation and Amortization 4.72 4.72
10% 10%
41%
EBIT (Operating Income) EBIT -165 -165
51% 51%
-1,439%
Net Profit -148 -148
57% 57%
-1,290%

In millions USD.

Don't miss a Thing! We will send you all news about Caribou Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Caribou Biosciences Stock News

Neutral
GlobeNewsWire
6 days ago
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in the following investor conferences:
Positive
Seeking Alpha
about 2 months ago
Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform offers precise genome editing and could potentially outperform competitors like Allogene Therapeutics. CRBU's flagship candidate, CB-010, shows promising results in Phase 1 trials for large B cell ...
Neutral
GlobeNewsWire
3 months ago
BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company leadership will participate in the following event and investor conferences:
More Caribou Biosciences News

Company Profile

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Head office United States
CEO Rachel Haurwitz
Employees 158
Founded 2011
Website www.cariboubio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today